Saxenda

What is Saxenda?

Saxenda is Novo Nordisk’s liraglutide 3 mg, approved in December 2014 for chronic weight management. That makes it the oldest weight-management drug in this class, approved seven years before Wegovy.

It is also the only one you inject every day. Every other injectable GLP-1 covered on this site is once weekly, and that difference is the thing people most often get wrong about Saxenda. The dose steps up on a weekly schedule, but the injection itself is daily.

Who is Saxenda approved for?

Adults with obesity, or adults with overweight plus at least one weight-related condition. The indication does not name a BMI number; the familiar thresholds describe who was enrolled in the trials.

It is also approved for adolescents, but the pediatric indication has three conditions that all have to be true: age 12 or older, obesity, and a body weight greater than 60 kg. That weight requirement is specific to Saxenda. Its safety and effectiveness in adolescents with type 2 diabetes have not been established.

The label also advises against taking it alongside another liraglutide product or any other GLP-1 medicine.

How much weight can you lose on Saxenda?

Less than on the newer drugs, and the page should say so plainly.

In the main 56-week trial, in people with obesity or overweight plus a comorbidity, weight fell 7.4 percent on average against 3.0 percent on placebo, a difference of 4.5 percentage points. About 62 percent of people lost at least 5 percent of their body weight, against 34 percent on placebo, and 34 percent lost more than 10 percent, against 15 percent.

In people who also had type 2 diabetes, the figures were smaller again: 5.4 percent against 1.7 percent.

For context, semaglutide produced about 15 percent in its own pivotal trial and tirzepatide about 21 percent in its own. Those are separate trials rather than head-to-head comparisons, so the numbers are not perfectly comparable, but the gap is far too large to be a close call. Saxenda is the honest low end of this class.

There is a third trial you may see quoted at 4.9 percent, and it should carry a warning: everyone in it had already lost at least 5 percent during a diet run-in before being randomized. The label itself says the results may not reflect what the general population would see.

In adolescents, the trial’s primary measure was a BMI standard deviation score rather than percent weight loss, because BMI in a growing teenager is not the same measure as adult body weight. That score fell 0.23 against essentially no change on placebo.

No trial figure is the drug alone. Every arm received structured lifestyle support, and individual results varied widely.

How does Saxenda work?

Liraglutide acts on the receptor for GLP-1, a hormone your gut already releases when you eat. Activating that receptor reduces appetite through the brain regions that handle hunger and food reward, and the weight loss comes mainly from eating less rather than burning more. It also slows stomach emptying, which adds to fullness and is where most of the nausea comes from.

Why daily rather than weekly is the interesting part, and it is not what most explanations claim. Liraglutide binds plasma protein above 98 percent and resists the enzyme that breaks GLP-1 down, which is the same strategy semaglutide uses. It still lasts only about 13 hours, against roughly a week for semaglutide. So the trick is not what sets the schedule; the degree of engineering is.

What are the side effects of Saxenda?

Mostly digestive, and its own rates sit at the higher end. Each figure below is from Saxenda’s adult trials against the placebo rate in those same trials.

Two readings worth getting right. Saxenda’s nausea rate of 39.3 percent looks higher than the weekly diabetes drugs, but it has never been compared head to head with them, and every label states that rates from separate trials cannot be ranked against each other. Read it against its own 13.8 percent placebo column. Similarly, injection-site reactions ran 13.9 percent against 10.5 percent on placebo, so the excess attributable to the drug is about 3.4 points, not 13.9.

About 9.8 percent of people stopped Saxenda because of side effects, against 4.3 percent on placebo, with nausea the leading reason.

The adolescent trial reported higher digestive rates than the adult one, with nausea at 42.4 percent and vomiting at 34.4 percent. Those are pediatric figures and should not be quoted as adult rates.

Unlike Ozempic or Mounjaro, Saxenda did carry the suicidality warning. It was one of only three products that ever had it, and it was removed in February 2026 after FDA reviewed the question and did not find that these drugs increase suicidal thinking or behavior. Ordinary vigilance still applies: tell your prescriber about new or worsening mood changes.

Because the drug slows stomach emptying, the label instructs patients to tell their care team before any procedure requiring general anesthesia or deep sedation. There is also a small increase in resting heart rate.

Who should not take Saxenda?

The boxed warning drives the first contraindication: because liraglutide caused thyroid C-cell tumors in rodents, anyone with a personal or family history of medullary thyroid cancer, or with MEN 2, should not take it.

Saxenda dosage: schedule and strengths

Saxenda climbs faster than the weekly drugs because it is taken daily. You start at 0.6 mg a day and increase every week until you reach 3 mg in week 5.

3 mg is the recommended dose, and the lower ones exist only to get you there. The label says to discontinue if you cannot tolerate 3 mg, with one exception: adolescents who cannot tolerate it may stay at 2.4 mg, and their escalation may take up to 8 weeks.

Saxenda also carries stopping rules the weekly drugs do not. Weight is reassessed 16 weeks after starting, and if you have not lost at least 4 percent of your starting weight, the label says to discontinue. For adolescents, BMI is checked after 12 weeks on the maintenance dose against a 1 percent threshold.

Missed doses work differently here too. There is no catch-up window: resume your usual daily dose at the next scheduled time. But if more than 3 days have passed since your last dose, the label says to restart at 0.6 mg and climb the ladder again.

How do you use the Saxenda pen?

The pen holds several daily doses and you attach a new needle each time. The steps below are a summary; follow the Instructions for Use that came with your pen.

1. Check the medicine and attach a new needle as your Instructions for Use direct.
2. Inject under the skin of the abdomen, thigh, or upper arm. On Saxenda all three are permitted for self-injection, which is not true of the tirzepatide products.
3. Use a different spot within that area each day.
4. Any time of day works, with or without meals. Pick a time you can keep.
5. Dispose of needles in a sharps container, and never share a pen with another person even with a new needle.

Storage follows the label for your product, and like every product in this class the in-use window is presentation-specific rather than a class rule.

How much does Saxenda cost?

We are not publishing a price for Saxenda yet, and the reason is worth stating plainly rather than filling the space with a number.

Our pricing evidence covers the newer products, and none of it covers Saxenda. Separately, generic liraglutide products now exist, which is unusual in this class and could change the picture substantially, since every other drug here is brand-only. Publishing a branded figure without accounting for that would likely mislead.

What we can say is how the landscape works. Coverage for obesity treatment is a patchwork: roughly a third of the largest employers cover it, far fewer state Medicaid programs do, and where coverage exists it often carries prior authorization, BMI rules, step therapy, or a lifestyle-program requirement. Medicare’s temporary GLP-1 Bridge does not include Saxenda; it covers Wegovy, Zepbound’s KwikPen, and Foundayo.

Ask your pharmacist about both the brand and any available generic liraglutide, and check your plan’s formulary directly.

Saxenda vs Wegovy, Zepbound, and Victoza

Saxenda vs Wegovy

Both are weight-management injections from Novo Nordisk, but Wegovy is weekly semaglutide and produced roughly double the weight loss in its own trials. Wegovy also carries a cardiovascular indication and Saxenda does not. Saxenda’s advantages are its longer track record and, occasionally, coverage. About Wegovy →

Saxenda vs Zepbound

Zepbound is weekly tirzepatide, with the largest average weight loss of any approved medication and an additional sleep-apnea indication. On magnitude this is not a close comparison. About Zepbound →

Saxenda vs Victoza

The same molecule at a different dose, for a different job. Victoza is liraglutide approved for type 2 diabetes; Saxenda is liraglutide 3 mg approved for weight management. Victoza’s cardiovascular outcome results belong to Victoza and do not transfer to Saxenda. About Victoza →

Looking beyond the brand? See every Saxenda alternative →

How to get Saxenda

Saxenda is prescription-only, and a licensed provider has to write it. Sites offering it without a prescription are not selling the approved product.

Saxenda myths and misconceptions

Five claims we hear constantly, and what is actually true.

• Myth Saxenda is a weekly shot like the others.

  It is daily. Saxenda is the only once-daily injection in this group, and the dose steps up weekly while you inject every day.

• Myth Saxenda and Victoza are interchangeable.

  Same molecule, different products. Saxenda is liraglutide 3 mg for weight management. Victoza is a lower dose for type 2 diabetes, and its cardiovascular results do not transfer to Saxenda.

• Myth Being older means it is better tested.

  It is well tested, with a large placebo-controlled trial pool. Older does not mean better here, it means the newer drugs have since produced roughly twice the weight loss.

• Myth The suicidality warning was never on this label.

  It was. Saxenda was one of only three products that carried it, and it was removed in February 2026 after FDA reviewed the question and did not find an increased risk.

• Myth If it is not working you should push through.

  The label disagrees. It sets a 16-week checkpoint and says to discontinue if you have not lost at least 4 percent of your starting weight, which is a rule the weekly drugs do not have.